Mumbai-based education finance non-banking financial company (NBFC) Avanse Financial Services, backed by global investors Warburg Pincus, Kedaara Capital, and Mubadala, is preparing to raise INR 1,374 crore (~USD 152 million) through a rights issue to existing shareholders. The move comes in the wake of the company’s decision to shelve its initial public offering (IPO) amid […]
Mumbai-based education finance non-banking financial company (NBFC) Avanse Financial Services, backed by global investors Warburg Pincus, Kedaara Capital, and Mubadala, is preparing to raise INR 1,374 crore (~USD 152 million) through a rights issue to existing shareholders. The move comes in the wake of the company’s decision to shelve its initial public offering (IPO) amid
Bengaluru health-tech platform opens early talks with bankers for Practo IPO; FY24 revenue at INR 240 crore, loss narrowed to INR 17 crore Practo Technologies is preparing to list in India in the second half of 2026, with early-stage discussions underway to appoint advisers as soon as next month. The company also plans to shift
Practo Begins Early Banker Talks For IPO, Targets H2 CY26 Listing Read More »
Bengaluru health-tech platform opens early talks with bankers for Practo IPO; FY24 revenue at INR 240 crore, loss narrowed to INR 17 crore Practo Technologies is preparing to list in India in the second half of 2026, with early-stage discussions underway to appoint advisers as soon as next month. The company also plans to shift
Practo Begins Early Banker Talks For IPO, Targets H2 CY26 Listing Read More »
Symbiotec Pharmalab, a research-driven pharmaceutical and biotechnology company based in Indore, Madhya Pradesh, has filed DRHP with the Securities and Exchange Board of India (SEBI). Symbiotec Pharmalab IPO comprises a fresh issue and an offer for sale—is expected to raise approximately INR 2,180.0 crore. Symbiotec Pharmalab IPO: Business Overview Founded in 2002, Symbiotec Pharmalab has
Indore-based Global Leader In Steroidal-Hormone APIs Files For ₹2,180 Cr IPO Read More »
Symbiotec Pharmalab, a research-driven pharmaceutical and biotechnology company based in Indore, Madhya Pradesh, has filed DRHP with the Securities and Exchange Board of India (SEBI). Symbiotec Pharmalab IPO comprises a fresh issue and an offer for sale—is expected to raise approximately INR 2,180.0 crore. Symbiotec Pharmalab IPO: Business Overview Founded in 2002, Symbiotec Pharmalab has
Indore-based Global Leader In Steroidal-Hormone APIs Files For ₹2,180 Cr IPO Read More »
Motilal Oswal Financial Services (MOFSL) has initiated coverage on Lodha Developers (LODHA) with a BUY recommendation and a target price of INR 1,888, implying a 73% upside from the current market price of INR 1,091. The brokerage’s conviction is anchored in Lodha’s accelerating presales momentum, disciplined balance sheet management, expanding multi-city footprint, and rising annuity
Motilal Oswal Financial Services (MOFSL) has initiated coverage on Lodha Developers (LODHA) with a BUY recommendation and a target price of INR 1,888, implying a 73% upside from the current market price of INR 1,091. The brokerage’s conviction is anchored in Lodha’s accelerating presales momentum, disciplined balance sheet management, expanding multi-city footprint, and rising annuity
Bengaluru-based social investing and market advisory platform StockGro’s Series B1 round has attracted USD 13 million (~INR 117 crore) from BITKRAFT Ventures as part of its Series B1 funding round, underscoring sustained investor confidence in India’s rapidly expanding retail investing ecosystem. StockGro Series B1 Funding & Use of Proceeds The company said the fresh capital
Bengaluru-based social investing and market advisory platform StockGro’s Series B1 round has attracted USD 13 million (~INR 117 crore) from BITKRAFT Ventures as part of its Series B1 funding round, underscoring sustained investor confidence in India’s rapidly expanding retail investing ecosystem. StockGro Series B1 Funding & Use of Proceeds The company said the fresh capital